Literature DB >> 18674685

Influence of Pro-Qura-generated plans on postimplant dosimetric quality: a review of a multi-institutional database.

Zachariah Allen1, Gregory S Merrick, Peter Grimm, John Blasko, John Sylvester, Wayne Butler, Usman-Ul-Haq Chaudry, Michael Sitter.   

Abstract

The influence of Pro-Qura-generated plans vs. community-generated plans on postprostate brachytherapy dosimetric quality was compared. In the Pro-Qura database, 2933 postplans were evaluated from 57 institutions. A total of 1803 plans were generated by Pro-Qura and 1130 by community institutions. Iodine-125 (125I) plans outnumbered Palladium 103 (103Pd) plans by a ratio of 3:1. Postimplant dosimetry was performed in a standardized fashion by overlapping the preimplant ultrasound and the postimplant computed tomography (CT). In this analysis, adequacy was defined as a V100 > 80% and a D90 of 90% to 140% for both isotopes along with a V150 < 60% for 125I and < 75% for 103Pd. The mean postimplant V100 and D90 were 88.6% and 101.6% vs. 89.3% and 102.3% for Pro-Qura and community plans, respectively. When analyzed in terms of the first 8 sequence groups (10 patients/sequence group) for each institution, Pro-Qura planning resulted in less postimplant variability for V100 (86.2-89.5%) and for D90 (97.4-103.2%) while community-generated plans had greater V100 (85.3-91.2%) and D90 (95.9-105.2%) ranges. In terms of sequence groups, postimplant dosimetry was deemed "too cool" in 11% to 30% of cases and "too hot" in 12% to 27%. On average, no clinically significant postimplant dosimetric differences were discerned between Pro-Qura and community-based planning. However, substantially greater variability was identified in the community-based plan cohort. It is possible that the Pro-Qura plan and/or the routine postimplant dosimetric evaluation may have influenced dosimetric outcomes at community-based centers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674685     DOI: 10.1016/j.meddos.2007.09.001

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  2 in total

1.  Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy.

Authors:  Michael J Zelefsky; Gil'ad N Cohen; Walter R Bosch; Lisa Morikawa; Najma Khalid; Cheryl L Crozier; W Robert Lee; Anthony Zietman; Jean Owen; J Frank Wilson; Phillip M Devlin
Journal:  Brachytherapy       Date:  2012-07-21       Impact factor: 2.362

2.  Real-time intraoperative computed tomography assessment of quality of permanent interstitial seed implantation for prostate cancer.

Authors:  Michael J Zelefsky; Mick Worman; Gilad N Cohen; Xin Pei; Marisa Kollmeier; Josh Yamada; Brett Cox; Zhigang Zhang; Eva Bieniek; Lawrence Dauer; Marco Zaider
Journal:  Urology       Date:  2010-11       Impact factor: 2.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.